Compare · BNTX vs SOPH
BNTX vs SOPH
Side-by-side comparison of BioNTech SE (BNTX) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $21.49B, about 56.8x SOPH ($378.4M).
- Over the past year, BNTX is down 21.5% and SOPH is up 82.9% - SOPH leads by 104.5 points.
- SOPH has been more active in the news (12 items in the past 4 weeks vs 8 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 13 for SOPH).
- Company
- BioNTech SE
- SOPHiA GENETICS SA
- Price
- $85.48-2.94%
- $5.25+6.28%
- Market cap
- $21.49B
- $378.4M
- 1M return
- -8.03%
- -2.78%
- 1Y return
- -21.55%
- +82.93%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 13
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- SEC Form 6-K filed by BioNTech SE
- Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
- BioNTech upgraded by UBS with a new price target
- Bernstein initiated coverage on BioNTech with a new price target
- SEC Form 6-K filed by BioNTech SE
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
- SEC Form 6-K filed by BioNTech SE
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
Latest SOPH
- Chief Financial Officer Cardoza George bought $99,000 worth of Ordinary Shares (20,000 units at $4.95), increasing direct ownership by 7% to 311,458 units (SEC Form 4)
- SEC Form 6-K filed by SOPHiA GENETICS SA
- SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center
- Chief Medical Officer Menu Philippe sold $24,774 worth of Ordinary Shares (5,000 units at $4.95) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 250,780 units (SEC Form 4)
- President Muken Ross sold $3,501 worth of Ordinary Shares (761 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.11% to 680,911 units (SEC Form 4) (tax liability)
- Chief Scientific Officer Xu Zhenyu sold $2,798 worth of Ordinary Shares (608 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.10% to 626,280 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Camblong Jurgi sold $20,658 worth of Ordinary Shares (4,486 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.12% to 3,629,495 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Menu Philippe sold $2,800 worth of Ordinary Shares (608 units at $4.61) as part of a pre-agreed trading plan, decreasing direct ownership by 0.24% to 255,780 units (SEC Form 4) (tax withholding)
- Chief Legal Officer Van Well Daan sold $3,149 worth of Ordinary Shares (684 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.20% to 345,052 units (SEC Form 4) to satisfy tax liability
- Chief People Officer Valente Manuela sold $1,747 worth of Ordinary Shares (380 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.18% to 214,691 units (SEC Form 4) (tax withholding)